Index of drugs

Treatment of chronic cerebral insufficiency, including conditions after ischemic stroke and vascular dementia. Mitigation of mental and neurological symptoms of cerebral circulation failure. Supportive therapy for chronic circulatory disorders in choroid and retina. Adjuvant therapy for vascular disorders.

1 tabl contains 5 mg of vinpocetine. The product contains lactose and wheat starch.

Vinpocetine exerts a protective effect on the brain as a result of a complex mechanism of action that positively influences brain metabolism and blood flow in the brain as well as the rheological properties of the blood. It leads to the improvement of brain metabolism, in particular the use of oxygen, increasing the oxygen distribution of glucose. It redirects the metabolism of Glucose in the brain to more beneficial oxygen metabolism, increases the brain's resistance to hypoxia and the concentration of ATP and cAMP in brain cells. In addition, it accelerates the metabolism of noradrenaline and serotonin in the brain. Vinpocetine acts as an antioxidant and increases the brain's tolerance to hypoxia. It leads to the improvement of cerebral circulation and oxygen transport to tissues, increasing the plasticity of erythrocytes, inhibits platelet aggregation and adhesion, and lowers pathologically increased blood viscosity. Increases blood flow through the brain and reduces peripheral vascular resistance, without affecting the systemic blood pressure, improves blood circulation in the ischemic area. Another mechanism of neuroprotective action of vinpocetine is the reduction of harmful cytotoxic reactions caused by amino acids, blocking of sodium channels and inhibition of NMDA and AMPA receptors. After oral administration, vinpocetine is rapidly and almost completely absorbed in the upper gastrointestinal tract. Bioavailability is 50-70%. C_max in the blood plasma after 1 h. Maximum concentrations in tissues were found 2-4 h after drug administration. About 66% is bound to plasma proteins. Vinpocetine is extensively metabolised in the liver; as a result of which its two main metabolites are formed: apovincaminic acid and hydroxywinpocetine. Biological T_0,5 vinpocetine in the elimination phase is 4.8-5 h. Excretion occurs mainly in the urine - unchanged and in the form of metabolites.

Hypersensitivity to the active substance Vinpocetine, alkaloidsvinca (vinblastine, vincristine) or any of the excipients. acute haemorrhagic stroke. Severe ischemic heart disease. Severe heart rhythm disturbances. Pregnancy and lactation. Children and adolescents (due to the lack of appropriate clinical trials on efficacy and safety in this age group).

Caution use in patients receiving antihypertensives as well as with hypotension or orthostatic hypotension. In patients with ECG changes and treated with drugs that cause ECG changes, an ECG should be performed. The preparation contains wheat starch, which may contain only traces of gluten, and therefore it is believed that it can be used safely in people with celiac disease (celiac disease). The preparation should not be used by patients with wheat allergy (other than visceral disease). The product contains lactose - should not be used in patients with rare hereditary galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose. 1 tabl contains 140 mg lactose - this should be taken into account in patients with diabetes mellitus.

The administration of vinpocetine during pregnancy and breastfeeding is contraindicated.

Uncommon: hypercholesterolemia, pain and dizziness, hypotension, dry mouth, nausea, stomach discomfort. Rare: leukopenia, thrombocytopenia, loss of appetite, diabetes, sleep disturbances, agitation, anxiety, dizziness, disturbance of taste, stupor, hemiplegia, drowsiness, amnesia, optic disc edema, hypersensitivity to sounds, hearing loss, tinnitus, ischaemia and (or) myocardial infarction, angina pectoris, bradycardia, tachycardia, additional arousal,palpitations, hypertension, thrombophlebitis, abdominal pain, constipation, diarrhea, indigestion, vomiting, erythema, hyperhidrosis, pruritus, urticaria, asthenia, fatigue, feeling hot, increased triglycerides in the blood, lowering the ST segment in the ECG, reducing and (or) an increase in the number of eosinophils, changes in liver enzymes. Very rare: anemia, agglutination of erythrocytes, hypersensitivity, euphoria, depression, tremors, convulsions, conjunctival congestion, arrhythmias, atrial fibrillation, dysphagia, stomatitis, dermatitis, chest discomfort, hypothermia, diminution and / or increase in the number of leukocytes, reduction in the number of erythrocytes, reduction in prothrombin time, weight gain.

Orally. Adults: The usual dose is 5 or 10 mg 3 times a day. The maximum daily dose is 30 mg. The maintenance dose is 15 mg per day. There is no need to reduce the dose in patients with impaired renal or hepatic function. The tablets should be taken after meals with water.